Fulcrum Therapeutics Stock Performance
| FULC Stock | USD 11.32 0.22 1.91% |
Fulcrum Therapeutics holds a performance score of 16 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.57, which means possible diversification benefits within a given portfolio. As returns on the market increase, Fulcrum Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fulcrum Therapeutics is expected to be smaller as well. Use Fulcrum Therapeutics jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Fulcrum Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Fulcrum Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent essential indicators, Fulcrum Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.91) | Five Day Return 2.91 | Year To Date Return 133.88 | Ten Year Return (16.15) | All Time Return (16.15) |
1 | Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 10/10/2025 |
2 | Acquisition by Ra Capital Management, L.p. of 237029 shares of Fulcrum Therapeutics at 5.495 subject to Rule 16b-3 | 10/23/2025 |
3 | What risks investors should watch in Fulcrum Therapeutics Inc. stock - Rate Hike Risk Managed Investment Entry Signals - newser.com | 10/27/2025 |
4 | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 | 10/29/2025 |
5 | FY2025 Earnings Forecast for FULC Issued By Leerink Partnrs | 11/05/2025 |
6 | Identifying reversal signals in Fulcrum Therapeutics Inc. - 2025 Support Resistance Fast Entry Momentum Alerts - newser.com | 11/11/2025 |
7 | Will Fulcrum Therapeutics Inc. stock beat EPS estimates - July 2025 Short Interest Technical Entry and Exit Tips - newser.com | 11/14/2025 |
8 | How Fulcrum Therapeutics Inc. stock compares to growth peers - Short Setup Smart Money Movement Alerts - newser.com | 11/17/2025 |
9 | Los Angeles Capital Management LLC Purchases Shares of 13,465 Fulcrum Therapeutics, Inc. FULC | 11/19/2025 |
10 | Truist Securities Initiates Buy Rating on Fulcrum Therapeutics FULC Stock News - GuruFocus | 11/24/2025 |
| Begin Period Cash Flow | 26.7 M | |
| Total Cashflows From Investing Activities | 32.2 M |
Fulcrum Therapeutics Relative Risk vs. Return Landscape
If you would invest 648.00 in Fulcrum Therapeutics on August 29, 2025 and sell it today you would earn a total of 484.00 from holding Fulcrum Therapeutics or generate 74.69% return on investment over 90 days. Fulcrum Therapeutics is currently generating 1.0083% in daily expected returns and assumes 4.9993% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Fulcrum, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fulcrum Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fulcrum Therapeutics, and traders can use it to determine the average amount a Fulcrum Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2017
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FULC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.0 actual daily | 44 56% of assets are more volatile |
Expected Return
| 1.01 actual daily | 20 80% of assets have higher returns |
Risk-Adjusted Return
| 0.2 actual daily | 16 84% of assets perform better |
Based on monthly moving average Fulcrum Therapeutics is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fulcrum Therapeutics by adding it to a well-diversified portfolio.
Fulcrum Therapeutics Fundamentals Growth
Fulcrum Stock prices reflect investors' perceptions of the future prospects and financial health of Fulcrum Therapeutics, and Fulcrum Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fulcrum Stock performance.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 441.72 M | ||||
| Shares Outstanding | 54.12 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 3.20 X | ||||
| Price To Sales | 5.12 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | (52.4 M) | ||||
| EBITDA | (18.24 M) | ||||
| Net Income | (9.72 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 8.63 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.67 X | ||||
| Cash Flow From Operations | (2.22 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 624.53 M | ||||
| Total Asset | 260.72 M | ||||
| Retained Earnings | (519.4 M) | ||||
| Working Capital | 238.88 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
About Fulcrum Therapeutics Performance
By analyzing Fulcrum Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Fulcrum Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Fulcrum Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Fulcrum Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (148.15) | (140.74) | |
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | (0.09) | (0.09) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about Fulcrum Therapeutics performance evaluation
Checking the ongoing alerts about Fulcrum Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fulcrum Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fulcrum Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 80 M. Net Loss for the year was (9.72 M) with loss before overhead, payroll, taxes, and interest of (52.4 M). | |
| Fulcrum Therapeutics currently holds about 221.79 M in cash with (2.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.26. | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: ADUS vs. USPH Which Stock Is the Better Value Option |
- Analyzing Fulcrum Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fulcrum Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fulcrum Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fulcrum Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fulcrum Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fulcrum Therapeutics' stock. These opinions can provide insight into Fulcrum Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Fulcrum Stock analysis
When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |